Increasing Value of Autopsies in Patients with Brain Tumors in the Molecular Era

Published in
Jared T. Ahrendsen, Mariella G. Filbin, Susan N. Chi, Peter E. Manley, Karen D. Wright, Pratiti Bandopadhayay, Jessica R. Clymer, Kee Kiat Yeo, Mark W. Kieran, Robert Jones, Hart G. Lidov, Keith L. Ligon & Sanda Alexandrescu
Default publication image


Pediatric brain tumors are associated with high morbidity and mortality, in part due to insufficient understanding of tumor biology. With limited tissue allocation for research from surgical specimens, a key barrier to improving biological understanding, brain tumor autopsies have become an increasingly valuable resource. This study reviews the brain tumor autopsy practice at our institution and describes specific emerging research utilization patterns beyond the clinical autopsy report.

Ninety-six deaths at BCH were due to brain tumors; 56 autopsies were performed (58.3%), of which 49 (87.5%) were consented for research. Tumor mapping was performed on all cases and tissue was allocated for DNA- and RNA-based sequencing studies (published and ongoing). Three tissue allocations with a postmortem interval of 8 h or less resulted in successful cell lines. Tissue from 14 autopsies was contributed to the National DIPG Registry.

Our institutional pediatric brain tumor autopsy clinical experience demonstrates the increased utility and wide utilization of autopsy-derived tissue for multiple types of research. These results support the increased efforts to obtain research consent for brain tumor autopsy and active collection of unfixed autopsy material in the molecular era.